Full-Time
Manager - FLEX and Intercompany Solutions
Information Technology, Business Operations
Posted on 9/15/2025
Pfizer
10,001+ employees
Biopharmaceutical company develops medicines and vaccines
No salary listed
Chennai, Tamil Nadu, India
Hybrid
Hybrid work arrangement.
 Data & Analytics (2) |
|---|
| , |
- Bachelor's Degree or equivalent experience, 5-12 years' experience working on SAP Sales and Distribution module (including Logistics Execution) including at least 2 years working on SAP S/4HANA.
- In-depth knowledge of integration points between SD and GTS, Finance, Manufacturing, Procurement and Quality
- Ability to define and understand business requirements, design SAP solutions and configure the system to meet the requirements.
- Ability to work with middleware team or ABAP/web developers to design, develop and test interfaces or system enhancements.
- Excellent written and verbal communication skills, with the ability to communicate with business and technical people alike.
- Excellent project management, analytical, leadership and inter-personal skills.
- Quick learner. Demonstrate initiative and ownership.
- Strong knowledge of Microsoft Office Products (including Teams)
- Lead and guide moderately complex projects, effectively managing time and resources
- Learn and gain expertise in Pfizer’s Intercompany Operations global model template and Pfizer’s Intercompany Automation Solution (FLEX). Also learn Pfizer’s Business Processes relevant to these solution areas.
- Collaborate with business users to understand business requirements, provide cost estimates and design SAP solutions to meet business requirements.
- Design and configure enhancements to SAP standard solution or new custom solution, and work with developers to implement the solution and perform testing as needed.
- Develop strong relationships at all levels in the organisation and collaborate with stakeholders with different cultural backgrounds and in different geographical regions.
- Lead teams of consultants and collaborate closely with regional and global Digital teams to deliver solutions in time and on budget.
- Communicate effectively with technical teams to get solutions developed and managing the business users’ expectations to ensure clear communication of the issues to seek input on a timely manner.
- Stay abreast of new technology trends and look for ways to apply next generation technologies such as AI and ML where it makes sense.
- Learn and adopt internal working procedures and foster conformance and standardization. Also suggest ways to improve procedures and practices.
- Master's degree.
- Relevant pharmaceutical industry experience.
- Experience with EDI Integration, Cloud for Customer (C4C)/Service Cloud, Fiori, BTP and Advanced ATP.
- Experience working on global programs.
- Understanding of Agile framework.
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Simplify's Take
What believers are saying
- Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
- VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
- ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.
What critics are saying
- Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
- Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
- Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.
What makes Pfizer unique
- Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
- Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
- Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Company News
ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich
Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.
Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.
Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.
Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.